Involved-Node Proton Therapy in Combined Modality Therapy for Hodgkin Lymphoma: Results of a Phase 2 Study

Abstract

Although decades of follow-up will be needed to realize the likely benefit of PT in reducing the risk of radiation-induced late effects, PT following chemotherapy in patients with HL is well-tolerated, and disease outcomes were similar to those of conventional photon therapy.

Comparative Risk Predictions of Second Cancers After Carbon-Ion Therapy Versus Proton Therapy

“…Scanned proton and carbon fields were planned to irradiate the clinical target volume (CTV) using a single anterior-to-posterior beam direction [21]. Ion pencil beams had focal spot sizes (in air) of 12.4 ± 1.7 mm full-width at half-maximum (FWHM) for protons and 7.0 ± 0.3 mm FWHM for carbon ions, typical of centers with active scanning beam delivery.…”

Recommendations for the Referral of Patients for Proton-Beam Therapy, an Alberta Health Services Report: A Model for Canada?

“…Studies of tumours outside the cns-including skull base chordoma and chondrosarcoma 22,23 , uveal melanoma 23,24 , germ-cell tumours 25 , high-risk neuroblastoma 26,27 , parameningeal rhabdomyosarcoma 28 , bladder and prostate rhabdomyosarcoma 29 , other soft tissue sarcomas 30 , Ewing sarcoma 31 , and mediastinal Hodgkin lymphoma 32 -uniformly showed that pbt is well tolerated, with local control rates similar to or higher than those achieved with photon rt. Although planning studies and early clinical results are promising, long-term data supporting a clear advantage of pbt over photon rt are not yet available.…”

État des lieux et perspectives de la protonthérapie

“…Selon le site tumoral et le type histologique, la réalisation d'essais de phase III qui nécessitent de longs suivis et des années d'étude peut s'avérer inutile et non éthique devant les avantage évidents au niveau dosimétrique [5].…”